Abstract:Background: Parkinson's disease (PD), Alzheimer's disease (AD) are common neurodegenerative disease, while mild cognitive impairment (MCI) may be happened in the early stage of AD or PD. Blood biomarkers are considered to be less invasive, less cost and more convenient, and there is tremendous potential for the diagnosis and prediction of neurodegenerative diseases. As a recently mentioned field, artificial intelligence (AI) is often applied in biology and shows excellent results. In this article, we use AI to model PD, AD, MCI data and analyze the possible connections between them. Method: Human blood protein microarray profiles including 156 CT, 50 MCI, 132 PD, 50 AD samples are collected from Gene Expression Omnibus (GEO). First, we used bioinformatics methods and feature engineering in machine learning to screen important features, constructed artificial neural network (ANN) classifier models based on these features to distinguish samples, and evaluated the model's performance with classification accuracy and Area Under Curve (AUC). Second, we used Ingenuity Pathway Analysis (IPA) methods to analyse the pathways and functions in early stage and late stage samples of different diseases, and potential targets for drug intervention by predicting upstream regulators. Result: We used different classifier to construct the model and finally found that ANN model would outperform the traditional machine learning model. In summary, three different classifiers were constructed to be used in different application scenarios, First, we incorporated 6 indicators, including EPHA2, MRPL19, SGK2, to build a diagnostic model for AD with a test set accuracy of up to 98.07%. Secondly, incorporated 15 indicators such as ERO1LB, FAM73B, IL1RN to build a diagnostic model for PD, with a test set accuracy of 97.05%. Then, 15 indicators such as XG, FGFR3 and CDC37 were incorporated to establish a four-category diagnostic model for both AD and PD, with a test set accuracy of 98.71%. All classifier models have an auc value greater than 0.95. Then, we verified that the constructed feature engineering filtered out fewer important features but contained more information, which helped to build a better model. In addition, by classifying the disease types more carefully into early and late stages of AD, MCI, and PD, respectively, we found that early PD may occur earlier than early MCI. Finally, there are 24 proteins that are both differentially expressed proteins and upstream regulators in the disease group versus the normal group, and these proteins may serve as potential therapeutic targets and targets for subsequent studies. Conclusion: The feature engineering we build allows better extraction of information while reducing the number of features, which may help in subsequent applications. Building a classifier based on blood protein profiles using deep learning methods can achieve better classification performance, and it can help us to diagnose the disease early. Overall, it is important for us to study neurodegenerative diseases from both diagnostic and interventional aspects.

The identification of cognitive impairment in Parkinson's disease using biofluids, neuroimaging, and artificial intelligence

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Simple biomarkers to distinguish Parkinson's disease from its mimics in clinical practice: a comprehensive review and future directions

Use of Magnetic Resonance Imaging and Artificial Intelligence in Studies of Diagnosis of Parkinson’s Disease

Diffusion and structural MRI as potential biomarkers in people with Parkinson’s disease and cognitive impairment

Artificial intelligence in Parkinson's disease: Early detection and diagnostic advancements

Magnetic Resonance Imaging Markers for Cognitive Impairment in Parkinson's Disease: Current View

Magnetic Resonance Imaging Markers for Cognitive Impairment in Parkinson’s Disease: Current View

Diagnostic AI Modeling and Pseudo Time Series Profiling of AD and PD Based on Individualized Serum Proteome Data

Intelligent Identification of Cerebrospinal Fluid for the Diagnosis of Parkinson's Disease.

Cognitive impairment in Parkinson's disease and other parkinsonian syndromes

Comprehensive serum metabolic and proteomic characterization on cognitive dysfunction in Parkinson’s disease

Machine learning for the detection and diagnosis of cognitive impairment in Parkinson's Disease: A systematic review

Predicting the occurrence of mild cognitive impairment in Parkinson's disease using structural MRI data

Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease

Parkinson disease-associated cognitive impairment

Navigating the Alzheimer's Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics

Research advancement in fluid biomarkers for Parkinson's disease

Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes

Diagnostic performance of artificial intelligence-assisted PET imaging for Parkinson's disease: a systematic review and meta-analysis

Artificial intelligence applied to neuroimaging data in Parkinsonian syndromes: Actuality and expectations